Harm reduction -: A treatment approach for resistant smokers with tobacco-related symptoms

被引:33
作者
Jiménez-Ruiz, C
Solano, S
Viteri, SA
Ferrero, MB
Torrecilla, M
Mezquita, MH
机构
[1] Hosp Princesa, Smokers Clin, Dept Pulmonol, E-28006 Madrid, Spain
[2] Hosp Clin Univ, Dept Pulmonol, Salamanca, Spain
关键词
chronic obstructive pulmonary disease; nicotine replacement therapy; smoking reduction; pulmonary function;
D O I
10.1159/000064015
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Smokers with chronic obstructive pulmonary disease (COPD) appear to represent a hard-core group, and this presents a dilemma for chest physicians. A reduction in cigarette smoking benefits health, and nicotine replacement therapy (NRT) can aid smoking reduction. Hence we studied the efficacy of nicotine gum in helping hardcore smokers with severe COPD to quit. Seventeen smokers with severe COPD (FEV1 38-47% of predicted normal) who smoked > 30 cigarettes/day but were unable to quit were encouraged to reduce their smoking as much as possible by using 4-mg nicotine gum. Five gradually reduced their daily tobacco consumption and, 18 months after starting NRT, were smoking an average of 6 cigarettes/day while still using nicotine gum. Compared to baseline, their respiratory symptoms had improved, and both FEV1 and FVC had increased. There was no improvement in pulmonary function in the group of smokers who did not reduce their cigarette consumption. No adverse events relating to nicotine occurred among the patients who used NRT to reduce their smoking. We propose that this reduction approach should be considered for patients with respiratory disease who are unable or unwilling to stop smoking. Copyright (C) 2002 S Karger AG, Basel.
引用
收藏
页码:452 / 455
页数:4
相关论文
共 19 条
[1]  
[Anonymous], HLTH CONS SMOK CHRON
[2]  
[Anonymous], 1990, HLTH BEN SMOK CESS R
[3]   EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[4]  
Benowitz NL, 1998, J PHARMACOL EXP THER, V287, P958
[5]   Smoking reduction with oral nicotine inhalers:: double blind, randomised clinical trial of efficacy and safety [J].
Bolliger, CT ;
Zellweger, JP ;
Danielsson, T ;
van Biljon, X ;
Robidou, A ;
Westin, Å ;
Perruchoud, AP ;
Säwe, U .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7257) :329-333
[6]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[7]   When does cigarette fading increase the likelihood of future cessation? [J].
Farkas, AJ .
ANNALS OF BEHAVIORAL MEDICINE, 1999, 21 (01) :71-76
[8]   Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study) [J].
Garcia-Aymerich, J ;
Barreiro, E ;
Farrero, E ;
Marrades, RM ;
Morera, J ;
Antó, JM .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (06) :1037-1042
[9]  
HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
[10]   The nicotine inhaler in smoking cessation [J].
Hjalmarson, A ;
Nilsson, F ;
Sjostrom, L ;
Wiklund, O .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (15) :1721-1728